Redx will become a key upcoming player in IPF treatment with FDA’s ODD for zelasudil: GlobalData
KOLs interviewed by GlobalData noted that there is a huge unmet need in the IPF space, which is pushing companies to look for…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic…
Under the License Agreement, Bridge Biotherapeutics will regain all rights to BBT-877
Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis
Cipla’s Nintib is priced at Rs 69 (100 mg) and Rs. 85 (150 mg) per capsule
BDR Pharma launches Nintenib (Nintedanib) to treat idiopathic pulmonary fibrosis in India
Nintenib is priced at Rs 750 (100 mg) and INR 900 (150 mg) for a pack of 10 tabs